ruzasvir

Ruzasvir is an investigational small molecule drug developed as a direct-acting antiviral for the treatment of hepatitis C virus (HCV) infection. It functions as a potent and pan-genotypic inhibitor of the nonstructural protein 5A (NS5A), which is essential for HCV replication. By inhibiting NS5A, ruzasvir disrupts viral RNA replication and assembly, leading to suppression of HCV in infected individuals. Ruzasvir has demonstrated high potency across all major HCV genotypes (GT1–GT7) in preclinical studies with picomolar EC50 values and has shown robust efficacy and safety in clinical trials when used in combination regimens—most notably with bemnifosbuvir or uprifosbuvir. The drug has been administered to over 2,100 patients at daily doses up to 180 mg for up to 12 weeks with a favorable safety profile and low risk of drug-drug interactions. Clinical development is ongoing primarily for chronic hepatitis C infection[1][3][4][6][7].

Other names

ruzasvir